FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913746369> ?p ?o ?g. }

• W2913746369 abstract "Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma with poor prognosis. RMS, and especially the embryonal subtype (ERMS), show activation of Hedgehog (HH) signaling. In patients with Gorlin syndrome, who have an increased susceptibility to ERMS, activation of the HH pathway is due to mutations in the HH receptor PATCHED (PTCH). This is different in sporadic RMS, in which mutations in components of the HH pathway are very rare. Because the HH pathway seems to be a good target for RMS therapy, we tested the effects of several SMOOTHENED (SMO) inhibitors on cell lines derived from sporadic human RMS. The response of the cells was very heterogeneous and some drugs paradoxically induced proliferation at certain concentrations or showed anti-proliferative effects without inhibition of HH signaling activity. Therefore we hypothesized that the antitumoral effects of SMO inhibitors may rely on off-target effects. In addition, our group found evidence for an interaction between HH and PI3K/AKT/mTOR signaling in RMS. Since the majority of RMS show phosphorylation of AKT or S6 and since an interaction between the PI3K/AKT/mTOR and HH signaling pathways is well described in the literature, this thesis elucidated the importance of PI3K/AKT/mTOR signaling in RMS and in regulation of HH signaling activity. Furthermore the effectiveness of PI3K/AKT/mTOR inhibitors alone and in combination with SMO inhibitors was analyzed. For this purpose cell lines from sporadic human ERMS and the Ptch+/- mouse model for ERMS were employed. In addition, we tried to unravel if the anti-cancer effects of SMO inhibitors that were not associated with a downregulation of HH signaling activity were off-target effects. The data show that cell lines from sporadic human ERMS are rather unresponsive to stimulation by the SHH ligand or SMO agonist. They are also only moderately responsive to SMO inhibitors, which apparently can exert off-target effects. However, they are highly responsive to PI3K/AKT/mTOR inhibitors, especially to the PI3K inhibitor pictilisib. Furthermore, PI3K/AKT/mTOR inhibitors can inhibit HH signaling activity in ERMS cells and when combined with SMO inhibitors they can induce cooperative anti-cancer effects. Because the investigated human ERMS cell lines in most likelihood do not harbor mutations that cause activation of HH signaling upstream of SMO and because the cells were only moderately responsive to SMO inhibitors, we hypothesized that SMO inhibitors alone are only useful in those ERMS that are caused by mutations upstream of SMO. To approach this hypothesis, we made use of ERMS-like tumors of Ptch mutant mice. Indeed, cultured Ptch+/- Abstract IV ERMS cells respond to SMO inhibitors, which goes along with efficient reduction of Hh signaling activity. In addition, and as in human ERMS cells, efficient reduction of Hh signaling activity and antitumor effects are also seen with the PI3K inhibitor pictilisib. Furthermore, the combination of SMO inhibitors plus pictilisib synergistically induces anti-cancer effects. When applied orally to tumor bearing Ptch+/- mice, SMO inhibitors stop tumor growth and downregulate Gli1 expression, which correlates with reduction of tumor size. Tumor growth is also stopped by pictilisib. However, in contrast to cultured Ptch+/- ERMS cells and human ERMS cell lines and probably due to microenvironmental factors, pictilisib does not affect Gli1 expression. In summary, the experiments of this thesis demonstrate that SMO inhibitors and concomitant reduction of HH signaling activity exhibit strong antitumoral effects in ERMS that harbor mutations upstream of SMO, whereas their antitumoral activity in cell lines derived from sporadic human ERMS (which most likely do not harbor mutations upstream of SMO) is very variable and not always associated with HH signaling inhibition. In contrast, PI3K/AKT/mTOR inhibitors e.g. pictilisib induce a strong antitumoral response irrespective of the mutational status of the HH pathway and in some cases also may allow for lowering the dose of SMO inhibitors. Together, these data suggest that PI3K/AKT/mTOR inhibitors are in general a better and probably a more secure therapeutic option in patients with sporadic ERMS and that a treatment with SMO inhibitors requires either pretesting e.g. in patient-derived short-term RMS cultures or a screen for PTCH mutations." @default.
• W2913746369 created "2019-02-21" @default.
• W2913746369 creator A5035799669 @default.
• W2913746369 date "2022-02-21" @default.
• W2913746369 modified "2023-09-30" @default.
• W2913746369 title "Targeting the Hedgehog and PI3K/AKT/mTOR signaling pathways in rhabdomyosarcoma" @default.
• W2913746369 cites W1486709967 @default.
• W2913746369 cites W1500729563 @default.
• W2913746369 cites W1507357096 @default.
• W2913746369 cites W1520162011 @default.
• W2913746369 cites W1527808522 @default.
• W2913746369 cites W1532326900 @default.
• W2913746369 cites W1547298604 @default.
• W2913746369 cites W1552798452 @default.
• W2913746369 cites W1570224939 @default.
• W2913746369 cites W1583334535 @default.
• W2913746369 cites W1585922331 @default.
• W2913746369 cites W1594815607 @default.
• W2913746369 cites W1855124090 @default.
• W2913746369 cites W1913521652 @default.
• W2913746369 cites W1926911210 @default.
• W2913746369 cites W1935464246 @default.
• W2913746369 cites W1963493384 @default.
• W2913746369 cites W1965568759 @default.
• W2913746369 cites W1966155043 @default.
• W2913746369 cites W1966917426 @default.
• W2913746369 cites W1966998932 @default.
• W2913746369 cites W1967178356 @default.
• W2913746369 cites W1970915933 @default.
• W2913746369 cites W1971947883 @default.
• W2913746369 cites W1976875150 @default.
• W2913746369 cites W1978714931 @default.
• W2913746369 cites W1981691061 @default.
• W2913746369 cites W1983341583 @default.
• W2913746369 cites W1984621921 @default.
• W2913746369 cites W1986178062 @default.
• W2913746369 cites W1986283384 @default.
• W2913746369 cites W1987860480 @default.
• W2913746369 cites W1989808605 @default.
• W2913746369 cites W1991251040 @default.
• W2913746369 cites W1992280242 @default.
• W2913746369 cites W1992844463 @default.
• W2913746369 cites W1992981977 @default.
• W2913746369 cites W1995338672 @default.
• W2913746369 cites W1997378257 @default.
• W2913746369 cites W1997862931 @default.
• W2913746369 cites W2000572318 @default.
• W2913746369 cites W2000992130 @default.
• W2913746369 cites W2002355858 @default.
• W2913746369 cites W2004063027 @default.
• W2913746369 cites W2005328929 @default.
• W2913746369 cites W2009147696 @default.
• W2913746369 cites W2009286988 @default.
• W2913746369 cites W2010237337 @default.
• W2913746369 cites W2010609060 @default.
• W2913746369 cites W2011070056 @default.
• W2913746369 cites W2012881327 @default.
• W2913746369 cites W2013699970 @default.
• W2913746369 cites W2017181626 @default.
• W2913746369 cites W2018835039 @default.
• W2913746369 cites W2019607817 @default.
• W2913746369 cites W2020691941 @default.
• W2913746369 cites W2023632790 @default.
• W2913746369 cites W2025663184 @default.
• W2913746369 cites W2026816359 @default.
• W2913746369 cites W2030573603 @default.
• W2913746369 cites W2032205265 @default.
• W2913746369 cites W2035000040 @default.
• W2913746369 cites W2035188131 @default.
• W2913746369 cites W2035548935 @default.
• W2913746369 cites W2036833206 @default.
• W2913746369 cites W2037917041 @default.
• W2913746369 cites W2040360122 @default.
• W2913746369 cites W2041442182 @default.
• W2913746369 cites W2041975075 @default.
• W2913746369 cites W2043289157 @default.
• W2913746369 cites W2044616474 @default.
• W2913746369 cites W2044965556 @default.
• W2913746369 cites W2047161681 @default.
• W2913746369 cites W2047680962 @default.
• W2913746369 cites W2048167482 @default.
• W2913746369 cites W2049342310 @default.
• W2913746369 cites W2051432136 @default.
• W2913746369 cites W2051754408 @default.
• W2913746369 cites W2052512448 @default.
• W2913746369 cites W2054683873 @default.
• W2913746369 cites W2054742531 @default.
• W2913746369 cites W2057793681 @default.
• W2913746369 cites W2059692699 @default.
• W2913746369 cites W2060776420 @default.
• W2913746369 cites W2061165132 @default.
• W2913746369 cites W2062703212 @default.
• W2913746369 cites W2062972691 @default.
• W2913746369 cites W2065322400 @default.
• W2913746369 cites W2065508488 @default.
• W2913746369 cites W2066711817 @default.
• W2913746369 cites W2067535881 @default.
• W2913746369 cites W2067942082 @default.
• W2913746369 cites W2068059122 @default.
• W2913746369 cites W2068912983 @default.

• next